Skip to main content

Cresemba Disease Interactions

There are 2 disease interactions with Cresemba (isavuconazonium).

Major

Isavuconazonium (applies to Cresemba) short QT

Major Potential Hazard, Moderate plausibility. Applicable conditions: Short QT Syndrome

Isavuconazonium shortened the QTc interval in a concentration-related manner. This drug is contraindicated in patients with familial short QT syndrome.

References

  1. (2015) "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc
Moderate

Isavuconazonium (applies to Cresemba) liver disease

Moderate Potential Hazard, Moderate plausibility.

The use of isavuconazonium has been associated with hepatic adverse reactions (e.g., elevations in ALT, AST, alkaline phosphatase, total bilirubin). Cases of more severe hepatic reactions (including hepatitis, cholestasis, hepatic failure including death) have been reported during therapy in patients with serious underlying medical conditions (e.g., hematologic malignancy). Liver-related laboratory tests should be evaluated at the start and during therapy. Isavuconazonium has not been studied in patients with severe liver dysfunction (Child-Pugh C) and should be used in these patients only when the benefits outweigh the risk. Clinical monitoring for drug-related side effects is recommended when treating patients with severe liver dysfunction.

References

  1. (2015) "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc

Cresemba drug interactions

There are 454 drug interactions with Cresemba (isavuconazonium).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer